Oct 4 (Reuters) - Italian pharma group Recordati (RECI.MI), opens new tab said on Friday it would buy from Sanofi (SASY.PA), opens new tab the global rights to a drug used to treat cold agglutinin ...

Milan, 4 th October 2024 – Recordati today announces an agreement with Sanofi to acquire the global rights to Enjaymo® (sutimlimab), a biologic which is the only approved targeted product for ...

Recordati will acquire global rights to Enjaymo for $825M upfront and up to $250M in milestone payments. Enjaymo generated €100M in revenue in 2024 and is expected to exceed €150M in 2025 ...

Recordati reached an agreement with French pharmaceutical company Sanofi to acquire the global rights to autoimmune disorder treatment Enjaymo for $825 million. The Italian pharmaceutical company ...

Ulm (ots) - Kurz nach 0.15 Uhr war ein 21-Jähriger mit seinem BMW auf der Kreisstraße 3021 zwischen Stetten ob Lontal und Hürben unterwegs. In einem Waldgebiet sprang plötzlich ein Reh über ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

As Sanofi continues to clean out its medicine chest, Italy’s Recordati is getting in on the action. Recordati is floating $825 million upfront—plus another $250 million in potential commercial ...

Investing.com -- Recordati 's (BIT:RECI) shares jumped on Friday following its deal with Sanofi (EPA:SASY) (NASDAQ:SNY) to buy the global rights to Enjaymo (sutimlimab), a first-in-class biologic for ...

On Friday, Italian pharma company Recordati S.p.A agreed to acquire the global rights to Enjaymo (sutimlimab) from Sanofi SA (NASDAQ:SNY) for $825 million as an upfront payment and additional ...

(Reuters) -Italian pharma group Recordati said on Friday it would buy from Sanofi the global rights to a drug used to treat cold agglutinin disease (CAD), a rare autoimmune disorder, for $825 ...

Subject to the closing date, Recordati expects minimal revenue contribution in 2024. The transaction is expected to be immediately accretive at the EBITDA level, with margin above the current Rare ...